Type 2 diabetes

HealthSnap Closes $25 Million Series B Funding Amidst Continued Triple Digit Growth of Remote Patient Monitoring and Chronic Care Management Platform

Retrieved on: 
Wednesday, February 21, 2024

MIAMI, Feb. 21, 2024 /PRNewswire/ -- HealthSnap, a Miami-based Remote Patient Monitoring (RPM) and Chronic Care Management (CCM) solution for healthcare providers, today announced its Series B financing totaling $25 million. The round was led by Sands Capital, with new investments from Comcast Ventures, Acronym Venture Capital, and Florida Opportunity Fund. Existing shareholders, Asclepius Growth Capital, Florida Funders, MacDonald Ventures, and TGH Ventures also participated in the round. Scott Frederick, a Managing Partner at Sands Capital, will join HealthSnap's board of directors.

Key Points: 
  • MIAMI, Feb. 21, 2024 /PRNewswire/ -- HealthSnap , a Miami-based Remote Patient Monitoring (RPM) and Chronic Care Management (CCM) solution for healthcare providers, today announced its Series B financing totaling $25 million.
  • Existing shareholders, Asclepius Growth Capital, Florida Funders, MacDonald Ventures, and TGH Ventures also participated in the round.
  • In the last 18 months, HealthSnap has grown exponentially, bolstered by the successful expansion of its market-leading Remote Patient Monitoring (RPM) platform with the addition of a comprehensive Chronic Care Management (CCM) solution.
  • HealthSnap is actively hiring for care navigator nurse positions, customer success managers, and patient enrollment specialists.

Inventiva reports preliminary 2023 fiscal year financial Information¹ and provides an update on its clinical trial NATiV3

Retrieved on: 
Thursday, February 15, 2024

Frédéric Cren, Chairman, Chief Executive Officer and cofounder of Inventiva, stated: “2023 has been an eventful year for the company.

Key Points: 
  • Frédéric Cren, Chairman, Chief Executive Officer and cofounder of Inventiva, stated: “2023 has been an eventful year for the company.
  • This allowed us to draw down the second tranche of €25 million of the €50 million EIB loan in January 2024.
  • We have advanced our pivotal NATiV3 Phase III clinical trial with lanifibranor in NASH after the implementation of the revised study design in early 2023, with 913 patients randomized to date.
  • An adverse event of elevated aminotransferases has been reported in a patient enrolled in the trial following a scheduled visit.

Nanox Receives FDA Clearance for HealthFLD, an Advanced AI-Based Software Empowering Clinicians in Assessment of Fatty Liver

Retrieved on: 
Tuesday, February 13, 2024

PETACH TIKVA, Israel, Feb. 13, 2024 (GLOBE NEWSWIRE) -- ("Nanox" or the "Company," Nasdaq: NNOX), an innovative medical imaging technology company, today announced that its deep-learning medical imaging analytics subsidiary, Nanox AI Ltd., received 510(k) clearance by the U.S. Food and Drug Administration (FDA) for HealthFLD, an artificial intelligence (AI) software that provides automated qualitative and quantitative analysis of liver attenuation from routine contrast and non-contrast chest and abdomen CT scans in patients between the ages of 18 to 75. HealthFLD is intended to support clinicians in the detection of fatty liver, correlated with hepatic steatosis, an early sign of metabolic dysfunction-associated steatotic liver disease (MASLD), formerly referred to as non-alcoholic fatty liver disease (NAFLD).

Key Points: 
  • HealthFLD is intended to support clinicians in the detection of fatty liver, correlated with hepatic steatosis, an early sign of metabolic dysfunction-associated steatotic liver disease (MASLD), formerly referred to as non-alcoholic fatty liver disease (NAFLD).
  • MASLD is commonly asymptomatic until it progresses to advanced liver fibrosis, and the current gold standard for diagnosis is a liver biopsy, which is invasive and costly.
  • HealthFLD was designed to help clinicians in the assessment and analysis of fatty liver in the general population from routine CT scans.
  • It’s promising to have a liver solution available that may help evaluate early signs of illness from routine imaging.”
    The HealthFLD clearance is the third product across the Nanox AI suite of population health solutions to receive FDA clearance.

Studies Explore: Semaglutide Use and Its Impact on Total Hip Arthroplasty Postoperative Outcomes

Retrieved on: 
Monday, February 12, 2024

SAN FRANCISCO, Feb. 12, 2024 /PRNewswire/ -- Ozempic and Wegovy, which both contain the active ingredient semaglutide, have received recent attention in the media and on social platforms for its effectiveness in supporting weight loss. Ozempic, which is approved for people with Type 2 diabetes, has now become a widely accepted choice for weight loss, and Wegovy was approved in 2021 for long-term weight management.

Key Points: 
  • As the use of semaglutide increases among patients for diabetes and/or weight management, it's important to understand how it can impact postoperative outcomes of joint replacement surgery.
  • Two studies presented at the AAOS 2024 Annual Meeting looked at the use of semaglutide and its impact on outcomes of total hip arthroplasty (THA), finding that patients who take semaglutide at the time of THA experience similar postoperative outcomes to those who do not take the drug.
  • The researchers found that postoperative complications after THA are similar between obese patients using semaglutide compared to those who did not.
  • Both cohorts experienced a similar risk of hip arthroplasty revision, prosthesis infection, opioid-related disorders, surgical site infections, mortality, respiratory failure, pulmonary embolism, deep vein thrombosis, postoperative dehydration, cardiovascular comorbidities, shock, and prosthesis dislocations.

Pre-diabetes gets its due: New $1.2 million award aimed at early intervention and treatment

Retrieved on: 
Friday, February 9, 2024

SAN ANTONIO, Feb. 9, 2024 /PRNewswire-PRWeb/ -- Is your A1C not quite high enough to be diabetes? It still could be serious.

Key Points: 
  • SAN ANTONIO, Feb. 9, 2024 /PRNewswire-PRWeb/ -- Is your A1C not quite high enough to be diabetes?
  • Moreover, the number of people with the condition is expected to double by 2030, with prevalence substantially higher in minority populations, including Hispanics.
  • A combination of lifestyle changes and medication can lead to a long-term prevention of progression to Type 2 diabetes.
  • "Proactive detection and early intervention of pre-diabetes will significantly decrease the progression of diabetes, with a tremendously positive impact in our community," Solis-Herrera said.

Better Therapeutics Signs Rebate Agreement with One of the Largest Pharmacy Benefit Managers in the US for its AspyreRx Diabetes Treatment

Retrieved on: 
Tuesday, February 6, 2024

Better Therapeutics Inc. (NASDAQ: BTTX), a pioneer in developing prescription digital therapeutics (PDTs) for treating cardiometabolic diseases, today announced that it has entered into a rebate agreement with one of the nation’s leading Pharmacy Benefit Managers (PBMs) negotiating on behalf of over 70 million lives in the US.

Key Points: 
  • Better Therapeutics Inc. (NASDAQ: BTTX), a pioneer in developing prescription digital therapeutics (PDTs) for treating cardiometabolic diseases, today announced that it has entered into a rebate agreement with one of the nation’s leading Pharmacy Benefit Managers (PBMs) negotiating on behalf of over 70 million lives in the US.
  • The rebate agreement, effective January 1, 2024, applies to the PBM’s commercial book of business and provides plan participants of the PBM the ability to add AspyreRx™ to their formularies with rebate eligibility.
  • Better Therapeutics launched AspyreRx in October 2023, after receiving U.S. Food and Drug Administration (FDA) authorization in July 2023 as the first prescription-only digital therapeutic to treat adults with type 2 diabetes (T2D).
  • “This rebate agreement opens up an important pathway for access to treatment for millions of patients with type 2 diabetes," said Frank Karbe , President and CEO at Better Therapeutics.

URMC Announces First-of-its-Kind Alliance to Expand Health Care Access to Rural Communities

Retrieved on: 
Tuesday, February 6, 2024

“This pilot is the next evolution, bringing telemedicine to those who may lack access to technology at home.

Key Points: 
  • “This pilot is the next evolution, bringing telemedicine to those who may lack access to technology at home.
  • “As a community bank serving much of Western and Central New York, we understand the unique challenges our rural communities face.
  • “A digital visit is a building block for patients to regain control of their wellness, and an opportunity for health systems to expand their footprint to deliver more care and services.”
    Americans living in rural regions experience significant health disparities, due in part to limited access to health care.
  • This pilot initiative will serve three rural communities – all with limited health care providers and where many residents lack broadband home internet.

NYU Langone Health Awarded $13 Million to Create National Center to Promote Diabetes Equity Research

Retrieved on: 
Tuesday, February 6, 2024

To generate more community-engaged diabetes research, the National Institute of Diabetes and Digestive and Kidney Diseases, a division of the National Institutes of Health, has pledged $13 million to NYU Langone Health, Albert Einstein School of Medicine/Montefiore Health System, and UCLA School of Medicine to create the National Center for Engagement in Diabetes Equity Research (CEDER), the first of its kind.

Key Points: 
  • To generate more community-engaged diabetes research, the National Institute of Diabetes and Digestive and Kidney Diseases, a division of the National Institutes of Health, has pledged $13 million to NYU Langone Health, Albert Einstein School of Medicine/Montefiore Health System, and UCLA School of Medicine to create the National Center for Engagement in Diabetes Equity Research (CEDER), the first of its kind.
  • Co-led by Nadia Islam, PhD, associate professor in the Institute for Excellence in Health Equity at NYU Langone, CEDER will create a centralized national infrastructure designed to foster community engagement and participation of diverse populations in Type 2 diabetes research.
  • "It is our hope that everyone committed to advancing equity in diabetes research and care can access the support and mentorship they need."
  • CEDER is funded by the National Institute of Diabetes and Digestive and Kidney Diseases.

The royals have historically been tight-lipped about their health – but that never stopped the gossip

Retrieved on: 
Tuesday, February 6, 2024

This is an unexpected announcement: it is unusual for the royal family to release details of medical conditions to the public.

Key Points: 
  • This is an unexpected announcement: it is unusual for the royal family to release details of medical conditions to the public.
  • For Queen Elizabeth II this attitude framed her response to public information about the royals, quipping “never complain, never explain”.
  • But the royals’ health has, occasionally, been the subject of official news, and, more commonly, the subject of gossip.

Henry VIII’s ‘soore legge’

  • Henry VIII’s (1491–1547) health was well-documented and discussed in state-papers and diplomatic dispatches of the day.
  • As Henry aged, his access to fine food led to an increase of weight.
  • Most of our knowledge today is gleaned from diplomatic reports sent by diplomats to their own leaders.
  • Read more:
    Henry VIII’s notes in prayer book written by his sixth wife reveal musings on faith, sin and his deteriorating health – new discovery

Queen Anne’s lupus

  • Queen Anne (1665-1714) had 17 pregnancies, 11 of which resulted in miscarriages or stillbirths, with the remainder all dying in childhood.
  • It is now believed Anne may have been afflicted with the autoimmune condition lupus.
  • For Anne’s contemporaries, the name of the illness perhaps mattered less than the real political issue it presented: who would become monarch after her?
  • With no heirs, there was real political fear her Catholic half-brother James Francis Edward Stuart (“The Old Pretender”) would claim the throne.

George III and mental illness


George III (1738–1820) famously suffered from bouts of mental illness, more recently been speculated to be caused by Porphyria, a hereditary blood disorder. Throughout his illness bulletins were issued by his doctors informing the public of his condition.

  • His repeated bouts of illness mean his health was a constant in the media of the time, with frequent, at times twice-daily, updates during episodes.
  • His illness called into question his ability to be monarch, a situation eventually resolved by the installing of his son, later George IV, as Prince Regent.

A family of haemophilia

  • This also came with a deadly legacy, haemophilia, given the moniker “the royal disease”.
  • Haemophilia is an inherited disorder which mostly affects males, where the blood does not clot properly.


While the royal family were careful to manage what information was publicly released about his illness, his status meant it garnered public attention. It was covered in medical journals of the time, and later in newspapers. As knowledge of the illness grew, both the public and members of the royal family were able to use it to guide decisions on marriages to limit its spread.

A new approach

  • Even her death certificate failed to reveal her cause of death, other than as old age.
  • After his recent prostate surgery, his office stated he wanted to inspire men to look after their prostates.
  • Now, the announcement of Charles’s cancer diagnosis signals a new approach by the royals.


The authors do not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and have disclosed no relevant affiliations beyond their academic appointment.

Trinity Biotech Announces Entry into a Letter of Intent with Bayer for a Joint Partnership to Launch a CGM Biosensor Device in China and India

Retrieved on: 
Wednesday, January 31, 2024

Both parties intend to negotiate a definitive agreement under the framework set by the Letter of Intent in the coming months.

Key Points: 
  • Both parties intend to negotiate a definitive agreement under the framework set by the Letter of Intent in the coming months.
  • In addition to the proposal to enter the Chinese market, the Letter of Intent includes a framework for the intention to launch a CGM device in India.
  • To date, CGM use in India is not widespread, but has been trending higher recently with increasing awareness about self-care.
  • Trinity Biotech will host a conference call on Wednesday, January 31 at 8:30 a.m. EST to discuss its recent Waveform acquisition.